Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.66 which represents a slight increase of $0.53 or 3.09% from the prior close of $17.13. The stock opened at $17.55 and ...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday in possible sympathy with Eli Lilly And Co’s (NYSE:LLY), ...

A representative at Hims states, “the online questionnaire is free and quite brief on the company website, and after the information is submitted, a healthcare provider will assess your ...

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission or other tangible benefit. Optum Store, Optum Perks, and Healthline ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no longer ...

For patients on a 12-month plan, Hims offers a semaglutide injection for $199 a month, according to its website. The news comes after U.S. Senator Bernie Sanders said multiple generic drugmakers ...

Hims & Hers Health Q3 2024 revenue projected to surpass estimates by $5M-$10M. Truist consumer survey shows 10% use compounded GLP-1 medications, while 14% prefer branded options. Thursday, The ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...